Table 2.

 Study population

	Treatment group
	Dihydrocodeine then nabilone			Nabilone then dihydrocodeine
	Patients (n)	Mean (SD)		Patients (n)	Mean (SD)
Demographic details
Female	25			21
Male	23			27
Age (years)	48	50.6 (15.2)		48	49.7 (12.0)
Height (cm)	48	168.6 (9.6)		48	169.0 (11.5)
Weight (kg)	48	73.9 (15.4)		48	77.7 (18.3)
Duration of pain (months)	48	79.8 (67.9)		48	73.0 (70.3)
Baseline visual analogue score	47	68.0 (12.4)		48	66.4 (14.9)
Neuropathic pain syndrome
Cervical radiculopathy	0			1
Complex regional pain syndrome	5			4
Demyelination	4			7
Diabetic neuropathy	4			3
Guillain-Barré syndrome	0			1
Mononeuritis multiplex	1			0
Myelopathy	2			4
Neuropathy	1			0
Post-herpetic neuralgia	4			3
After injury or surgery	22			20
Spinal artery thrombosis	2			0
Spinal cord injury	1			0
Transverse myelitis	1			4
Trigeminal neuralgia	1			1
Previous treatment with non-steroidal anti-inflammatory drugs
No	16			9
Yes	32			39
Previous treatment with weak opioid
No	10			6
Yes	38			42
Previous treatment with antidepressant
No	5			7
Yes	43			41
Previous treatment with anticonvulsant
No	7			9
Yes	41			39
Previous treatment strong opioid
No	37			29
Yes	11			19
Signs of sensory abnormality
No	3			3
Yes	45			45
Signs of allodynia
No	22			15
Yes	26			33
Symptoms of burning pain
No	16			14
Yes	32			34
Symptoms of lancinating pain
No	5			7
Yes	43			41
Symptoms of sympathetic dysfunction
No	35			38
Yes	13			10
Origin of pain
Central	10			20
Peripheral	38			28